Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedDec 26, 2025
DataAggregated Company Financials
Companies21
  • 7D5.3%
  • 3M-2.8%
  • 1Y-41.4%
  • YTD-41.6%

Over the last 7 days, the Healthcare industry has risen 5.3%, driven by gains from Novo Nordisk of 7.0%. In contrast, the industry has lost 41% in the last 12 months. Earnings are forecast to grow by 4.5% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 27 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Mon, 24 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b17.1x13.5x4.1x
Wed, 22 Oct 2025DKK 2.1tDKK 447.6bDKK 141.8b19.2x14.9x4.7x
Fri, 19 Sep 2025DKK 2.2tDKK 447.2bDKK 141.6b19.1x15.8x5x
Sun, 17 Aug 2025DKK 1.9tDKK 444.4bDKK 140.2b28.1x13.6x4.3x
Tue, 15 Jul 2025DKK 2.4tDKK 423.2bDKK 124.5b29.9x19.4x5.7x
Thu, 12 Jun 2025DKK 2.8tDKK 423.6bDKK 124.6b31.3x22.3x6.6x
Sat, 10 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Mon, 07 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b22.8x19.4x5.8x
Wed, 05 Mar 2025DKK 3.3tDKK 410.0bDKK 121.4b26.9x26.8x7.9x
Fri, 31 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b28.6x29.2x8.4x
Sun, 29 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Tue, 26 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31.2x34.7x10x
Thu, 24 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b34.2x38.4x11.1x
Sat, 21 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Mon, 19 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.2x43.9x12.7x
Wed, 17 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.2x46.1x13.8x
Fri, 14 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b36.4x46.6x13.9x
Sun, 12 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Tue, 09 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.9x13.1x
Thu, 07 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38.2x44.3x12.9x
Sat, 03 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Mon, 01 Jan 2024DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Wed, 29 Nov 2023DKK 3.6tDKK 320.4bDKK 90.0b33x39.7x11.2x
Fri, 27 Oct 2023DKK 3.5tDKK 305.7bDKK 82.3b26.7x42.5x11.4x
Sun, 24 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Tue, 22 Aug 2023DKK 3.3tDKK 303.6bDKK 81.3b36.3x40.8x10.9x
Thu, 20 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.7x10.2x
Sat, 17 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Mon, 15 May 2023DKK 3.2tDKK 284.8bDKK 74.9b41.2x43.1x11.3x
Wed, 12 Apr 2023DKK 3.0tDKK 272.6bDKK 68.5b42.9x43.7x11x
Fri, 10 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.5x40.7x9.6x
Sun, 05 Feb 2023DKK 2.7tDKK 285.9bDKK 69.0b38.1x38.9x9.4x
Tue, 03 Jan 2023DKK 2.7tDKK 276.0bDKK 66.3b37.3x40.6x9.8x
Price to Earnings Ratio

40.6x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 276.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 34.2x20242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 14.4x which is lower than its 3-year average PE of 34.2x.
  • The 3-year average PS ratio of 9.6x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market2.09%
Healthcare5.30%
Healthcare Services7.22%
Pharma6.52%
Biotech2.60%
Life Sciences0.088%
Medical Equipment-0.47%
Healthtech-3.37%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 158x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 94% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 20% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 331.557.0%
+DKK 95.8b		-47.9%PE14.2x
GMAB GenmabDKK 2.12k3.2%
+DKK 4.0b		40.8%PE13x
DEMANT DemantDKK 214.001.3%
+DKK 596.4m		-19.6%PE17.1x
ZEAL Zealand PharmaDKK 483.001.6%
+DKK 541.2m		-34.2%PE5.2x
ALK B ALK-AbellóDKK 227.600.4%
+DKK 177.0m		42.1%PE45.7x

Latest News

ZEAL
DKK 483.00
Zealand Pharma
7D
1.6%
1Y
-34.2%

ZEAL: Next Generation Metabolic Partnership Will Drive Future Upside Potential

Analysts have nudged their price target for Zealand Pharma slightly higher to approximately $774 per share from about $773, citing modestly lower discount rate assumptions. These more than offset slightly weaker long term revenue growth and profit margin expectations.
NOVO B
DKK 331.55
Novo Nordisk
7D
7.0%
1Y
-47.9%

NOVO B: Future Returns Will Rely On Durable Obesity And Diabetes Cash Flows

Analysts have nudged their fair value estimate for Novo Nordisk slightly lower by about $0.25 per share to roughly $393.04, reflecting modestly softer long term revenue growth assumptions even as profit margin and valuation expectations remain broadly intact. Analyst Commentary Analyst sentiment around Novo Nordisk remains broadly constructive, with the slight fair value adjustment seen more as a recalibration of growth expectations than a shift in the underlying thesis.
ALK B
DKK 227.60
ALK-Abelló
7D
0.4%
1Y
42.1%
DEMANT
DKK 214.00
Demant
7D
1.3%
1Y
-19.6%
GUBRA
DKK 517.00
Gubra
7D
-0.1%
1Y
-17.9%
BAVA
DKK 189.45
Bavarian Nordic
7D
0.1%
1Y
-2.4%
COLO B
DKK 542.80
Coloplast
7D
-0.9%
1Y
-31.7%
EMBLA
DKK 32.80
Embla Medical hf
7D
-2.7%
1Y
-6.0%

EMBLA: Ukraine Expansion And Margin Outlook Will Support Steady Future Performance

Analysts have raised their price target for Embla Medical hf. from approximately 28.00 dollars to 34.00 dollars, reflecting expectations for slightly faster revenue growth, improving profit margins, and a higher justified future earnings multiple, despite a modestly higher discount rate.
SMSMED
DKK 4.75
Scandinavian Medical Solutions
7D
7.2%
1Y
-14.3%
GMAB
DKK 2,123.00
Genmab
7D
3.2%
1Y
40.8%

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
HLUN B
DKK 43.00
H. Lundbeck
7D
-0.5%
1Y
2.8%

HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares

Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.
BIOPOR
DKK 1.04
BioPorto
7D
-1.9%
1Y
-26.2%
VIRO
DKK 12.05
ViroGates
7D
-7.3%
1Y
7.6%
PEG
DKK 0.094
Pharma Equity Group
7D
-3.7%
1Y
-47.9%
NNIT
DKK 47.95
NNIT
7D
-3.6%
1Y
-49.0%
CHEMM
DKK 683.50
ChemoMetec
7D
0.2%
1Y
34.5%